The onco-cardiology ESC guideline recommends the baseline measurement of BNP/NT pro-BNP and/or cTn in all patients with cancer at risk of cancer therapy-related cardiac dysfunction (CTRCD) if these biomarkers are going to be measured during treatment [40]. Here, NPPB is linked to cancer.